Acusphere, Inc. to Host Conference Call to Discuss 2004 Q4 Results

    Business Editors/Health Editors

    WATERTOWN, Mass.--(BUSINESS WIRE)--March 10, 2005--Acusphere, Inc. (NASDAQ: ACUS) a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology, today announced that it expects on Tuesday, March 15, 2005, to report results for its fourth quarter ended December 31, 2004. The Company also announced that it plans to hold a conference call starting at 5:00 pm (EST) on Tuesday, March 15, 2005 to discuss its financial results, its quarterly highlights and business outlook.
    To listen to this conference call via live audio webcast, please visit the Investor Relations section of the Company's website (www.acusphere.com) at least ten minutes prior to the start of the call and follow the directions there. The webcast will also be available as a replay, starting approximately one hour after the call is finished, through March 31, 2005. Alternately, to access the call via live telephone, please dial 1-800-229-0433, using confirmation code 75501838. Internationally, the call may be accessed by dialing 1-617-801-9712, using the same confirmation code.
    In addition to the webcast replay, a telephone replay will be available from approximately 7:00 pm (EST) on March 15, 2005 through March 31, 2005. To access the replay please call 1-888-286-8010 and use the confirmation code of 67223771. Replay is also available internationally at 1-617-801-6888 using the same confirmation code, 67223771.

    About Acusphere, Inc.

    Acusphere (NASDAQ:ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. Acusphere's lead product candidate, AI-700, is a cardiovascular drug in Phase 3 clinical development. AI-700 is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary heart disease. An estimated 9.5 million procedures are done each year in the U.S. to detect coronary heart disease, the leading cause of death in the United States. Acusphere's product candidates have been created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. For more information about Acusphere visit the Company's web site at www.acusphere.com.

    "Acusphere" is trademarks of Acusphere, Inc.

--30--MA/bo*

CONTACT: Acusphere, Inc. John F. Thero, 617-648-8800 or Investors: 617-925-3444 IR@acusphere.com or Media: (617) 648-8800

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BANKING BIOTECHNOLOGY CONFERENCE CALLS SOURCE: Acusphere, Inc.

Copyright Business Wire 2005